◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Abbott India Limited (ABBOTINDIA) EPS 2023–2026

Name: Abbott India Limited (ABBOTINDIA) eps history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Abbott India Limited annual earnings per share (EPS) for fiscal 2026 was ₹730.36, an increase of 9.7% from ₹665.62 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ABBOTINDIA Annual EPS

EPS (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Diluted EPS	₹730M	₹666M	₹565M	₹447M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBOTINDIA Quarterly EPS

EPS (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Diluted EPS	₹202M	₹186M	₹177M	₹195M	₹172M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

MANKIND EPS — Mankind Pharma Limited
4506 EPS — Sumitomo Pharma Co., Ltd.
GLENMARK EPS — Glenmark Pharmaceuticals Limited
ALKEM EPS — Alkem Laboratories Limited
IPCALAB EPS — Ipca Laboratories Limited
GLAND EPS — Gland Pharma Limited

More ABBOTINDIA metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow

All ABBOTINDIA financial statements → Interactive ABBOTINDIA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.